Abstract:Background: This study aimed to screen potential drugs targeting a new prognostic gene signature associated with proliferation in hepatocellular carcinoma (HCC). Methods: CRISPR Library and TCGA datasets were used to explore differentially expressed genes (DEGs) related to the proliferation of HCC cells. Differential gene expression analysis, univariate COX regression analysis, random forest algorithm and multiple combinatorial screening were used to construct a prognostic gene signature. Then the predictive power of the gene signature was validated in the TCGA and ICGC datasets. Furthermore, potential drugs targeting this gene signature were screened. Results: A total of 640 DEGs related to HCC proliferation were identified. Using univariate Cox analysis and random forest algorithm, 10 hub genes were screened. Subsequently, using multiplex combinatorial screening, five hub genes (FARSB, NOP58, CCT4, DHX37 and YARS) were identified. Taking the median risk score as a cutoff value, HCC patients were divided into high- and low-risk groups. Kaplan-Meier analysis performed in the training set showed that the overall survival of the high-risk group was worse than that of the low-risk group (p < 0.001). The ROC curve showed a good predictive efficiency of the risk score (AUC > 0.699). The risk score was related to gene mutation, cancer cell stemness and immune function changes. Prediction of immunotherapy suggetsted the IC50s of immune checkpoint inhibitors including A-443654, ABT-888, AG-014699, ATRA, AUY-922, and AZ-628 in the high-risk group were lower than those in the low-risk group, while the IC50s of AMG-706, A-770041, AICAR, AKT inhibitor VIII, Axitinib, and AZD-0530 in the high-risk group were higher than those in the low-risk group. Drug sensitivity analysis indicated that FARSB was positively correlated with Hydroxyurea, Vorinostat, Nelarabine, and Lomustine, while negatively correlated with JNJ-42756493. DHX37 was positively correlated with Raltitrexed, Cytarabine, Cisplatin, Tiotepa, and Triethylene Melamine. YARS was positively correlated with Axitinib, Fluphenazine and Megestrol acetate. NOP58 was positively correlated with Vorinostat and 6-thioguanine. CCT4 was positively correlated with Nerabine. Conclusion: The five-gene signature associated with proliferation can be used for survival prediction and risk stratification for HCC patients. Potential drugs targeting this gene signature deserve further attention in the treatment of HCC.

Liver Tissue-specific Genes IGFALS,CYP3A4,SLC22A1 and CYP2E1 May Be Associated with Poor Prognosis of Liver Cancer

Computational analysis for identification of early diagnostic biomarkers and prognostic biomarkers of liver cancer based on GEO and TCGA databases and studies on pathways and biological functions affecting the survival time of liver cancer

Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma

Identification of genes in hepatocellular carcinoma induced by non-alcoholic fatty liver disease

[A bioinformatics analysis of differentially expressed genes associated with liver cancer]

Identification of prognosis-related genes in hepatocellular carcinoma based on bioinformatical analysis

Integrated Bioinformatics Analysis Reveals Key Candidate Genes and Pathways Associated with Clinical Outcome in Hepatocellular Carcinoma

Bioinformatics Analysis to Identify the Key Genes Affecting the Progression and Prognosis of Hepatocellular Carcinoma

Key genes associated with non-alcoholic fatty liver disease and hepatocellular carcinoma with metabolic risk factors

Bioinformatics Analysis Using ATAC-seq and RNA-seq for the Identification of 15 Gene Signatures Associated With the Prediction of Prognosis in Hepatocellular Carcinoma

Evaluation of TGFβ, XPO4, Elf5a2 and ANGPTL4 As Biomarkers in HCC

Prognostic Biomarkers for Hepatocellular Carcinoma Based on Serine and Glycine Metabolism-related Genes

Integrated analysis of genes associated with poor prognosis of patients with colorectal cancer liver metastasis

Novel Prognostic Markers for Liver Hepatocellular Carcinoma and Their Roles in Immune Infiltration of the Tumor Microenvironment

From Big Data to Diagnosis and Prognosis: Gene Expression Signatures in Liver Hepatocellular Carcinoma

Bioinformatics screening of biomarkers related to liver cancer

Prognosis-Related Molecular Subtypes and Immune Features Associated with Hepatocellular Carcinoma

Genes co-related with poor prognosis of patients with lung cancer via bioinformatical approaches

Integrated Proteomics and Bioinformatics to Identify Potential Prognostic Biomarkers in Hepatocellular Carcinoma

[Exploration of cystathionine β-synthase and cystathionine γ-lyase gene expression poor prognostic predictive value with the application of bioinformatics data mining in liver cancer]

Machine Learning Screens Potential Drugs Targeting a Prognostic Gene Signature Associated With Proliferation in Hepatocellular Carcinoma